Although revenues increased during the current quarter ended March 31, 2005, Trimedyne had a net loss of $24,000 or $0.00 per share, compared to a net profit of $149,000 or $0.01 per share in the prior year quarter.   However, the profit for the prior year quarter included the benefit of $177,000 of other income, whereas other income in the current quarter was $45,000 and R & D costs in the current quarter increased 53% to $144,000 in the current year quarter from $94,000 during the same quarter of the prior year.

       As a percentage of sales, compared to the same quarter of the prior year, the Company’s cost of goods decreased to 49% from 53%, SG&A increased to 45% from 42%, R&D expenses rose to 10% from 7% and gross profit increased to 51% from 48%.

       For the six months ended March 31, 2005, the Company had a net profit of $149,000 or $0.01 per share, compared to a net profit of $314,000 or $0.02 per share in the same period of the prior year.  The profit for the six-month period of the prior year included the benefit of $300,000 of other income, whereas other income in the current six-month period was $45,000.  R & D costs in the current six-month period increased to $277,000 from $161,000 during the same period of the prior year.  As a percentage of sales, compared to the same period of the prior year, the cost of goods decreased to 50% from 52%, SG&A decreased to 39% from 41%.  R & D expenses increased to 9% from 6% and gross profit increased to 50% from 48%.

       Glenn D. Yeik, President of Trimedyne, said, “We are pleased to report an increase in sales in the current quarter and six month periods, compared to the year ago periods.  We have achieved a net profit for the first six months of this year, despite the increase in SG&A due to the loss in sub-lease income and increase in R&D due to increased development of new products. We are planning to introduce some new products shortly, and as a result, marketing expenses are expected to rise in the coming months.  We anticipate our revenues will increase from sales of the new products, although such cannot be assured.”

       Trimedyne manufactures lasers and proprietary fiber optic devices for a variety of minimally invasive surgical procedures, many of which are performed on an outpatient basis at substantially less cost than conventional surgery.  For product, financial and other information, visit Trimedyne's website, http://www.trimedyne.com.

 "Safe Harbor" Statement Under the Private Securities Litigation Reform Act:

       Statements in this news release may contain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1993 and Section 21E of the Securities and Exchange Act of 1934.  Such statements may involve various risks and uncertainties, some of which may be discussed in the Company's most recent report on Form 10-KSB and subsequently filed SEC reports.  There is no assurance any new products can be cleared for sale by the FDA or successfully commercialized or any forward-looking statements will prove accurate, as actual results and future events could differ materially from those presently anticipated.